Opinion
Video
Overview of Molecular Testing and Barriers in mCRC
The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.
Now Viewing
EP: 1.Overview of Molecular Testing and Barriers in mCRC
EP: 2.Clinical Considerations for 2L Treatment Sequencing in mCRC
EP: 3.Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
EP: 4.Exploring Toxicities for Second Line Treatments in mCRC
EP: 5.Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
EP: 6.Factors Driving 3L Therapeutic Selection for mCRC
EP: 7.Exploring Data Outcomes From the SUNLIGHT Trial
EP: 8.Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
EP: 9.Examining the Evolving 3L Treatment Landscape for mCRC
EP: 10.Additional Key Takeaways of ASCO 2024 Data in mCR
EP: 11.Future Outlooks in the Treatment of Metastatic Colorectal Cancer
- Dr Marshall to Dr Cohen: How would you describe the role of molecular testing for patients with mCRC?
- Which biomarkers are recommended for testing and when are patients tested?
- Dr Marshall to Panel: Briefly describe commonly used testing strategies of molecular markers for patients with mCRC.
- Is there a continued role for ctDNA in molecular testing for patients with mCRC?
- Dr Benson: What are some barriers to molecular testing in practice?
Related Videos
Related Content
